Projects
The neuroprotection after a first-episode mania episode
Together with members of ORYGEN and Barwon Health, we have recently secured significant funding to conduct detailed investigations of the neuroprotective effects of quetiapine, which has traditionally been used as an antipsychotic, but whose efficacy as a mood-stabilizing agent is being increasingly recognized, and which may provide an effective alternative to lithium. Detailed longitudinal neuroimaging assessments of patients with bipolar disorder prescribed one or the other treatment will allow direct comparison of their effects on brain structure and function (including the prefrontal, anterior cingulate and hippocampal/amygdala regions), and how these, in turn, influence clinical outcome. This is the first maintenance study following a first episode of illness in the literature, and the first study with neuroprotection as a primary endpoint.
Investigators
Prof Michael Berk, A/Prof Murat Yucel, Dr Peter Brotchie, Dr Karen Hallam, Nellie Lucas, Dr Craig Macneil, Prof Patrick McGorry
Research Assistant
Erin Bariball, Michaela O’Regan
Ethics
Melbourne Health: MHREC 2006.044
Project Title: Neuroprotective Properties of Quetiapine versus Lithium in a First Episode Mania Cohort: 12-month Neuroanatomical, Neurochemical and Neuro-cognitive Effects and Preliminary Data of Prophylactic Properties
Investigator: Professor Michael Berk